Innovation

Australia’s EMVision takes world lead in portable brain scan devices

By Leon Gettler, Talking Business >>

IMAGINE a tool that protects people from stroke, a tool that you can use by the bedside or even in the driveway. This potentially could replace, or at least add to, the equipment now found in hospitals to examine the brain, such as CT scans and MRI machines.

This is precisely the device – so to be devices – being developed by EMVision, a listed company which was spun out of the University of Queensland (UQ). EMVision is today based in Sydney.

EMVision CEO Ron Weinberger said EMVision’s portable imaging devices were specifically aimed at dealing with the classification of stroke.

“It’s a fast, reliable, safe cost-effective point of care way of actually looking at patients with brain injury,” Dr Weinberger told Talking Business

“It’s not just stroke we can look at. We can look at brain injury in general, but we are starting on stroke because of the huge unmet need and health economic burden around the world.

“Why we are looking at stroke is that one of the issues is there isn’t any other way – by the bedside or in the driveway of a home – that you can actually look at a patient’s brain in a portable way.”

Dr Weinberger said the University of Queensland had been working on this device for 10 years and EMVision had been spun out of UQ’s start-up incubator unit, Uniquest, and the devices had subsequently been developed over two years,

“We’ve accelerated very rapidly from the work done in a laboratory to the work we’ve been able to do as a commercial entity,” Dr Weinberger said.

UQ continues to back EMVision

UQ is a shareholder in EMVision and one of the inventors, professor Stuart Crozier, now works as EMVision’s chief scientific officer. He was involved originally in detecting magnetic field distortion in MRIs and 60 percent of MRIs have the technology he developed.

One of the issues for the company is that the location of EMVision’s product development team is in Sydney and its relationship with UQ is in Queensland. That creates a ‘tyranny of distance’ as well as a different mindset for solving problems.

EMVision has its own product development team at Macquarie Park, Sydney.

It is also commercialising the device by working with potential partners in the large imaging companies such as GE and Siemens.

Dr Weinberger said EMVision was drawing talent for its team from all over the world.

He said the company’s recent listing on the Australian Securities Exchange (ASX) was important because EMVision needed patient capital and access to capital markets.

“The listing allowed us to have incredible investors,” Dr Weinberger said.

He said the listing brought a new level of structure to the way EMVision operates. 

“The governance and transparency that’s required in a listed environment brings a level of functionality that you normally wouldn’t have to have in a business. You can look at it as a burden, In our case it’s been very much as a plus,” Dr Weinberger said.

“Working in a listed environment allows you to manage your governance issues with research institutions and all other third parties that you might be working with.”

He said EMVision works closely with hospitals and the Australian Stroke Alliance.

“We’re going to change the nature of stroke diagnosis and imaging,” he said.

www.emvision.com.au

www.leongettler.com

 

Hear the complete interview and catch up with other topical business news on Leon Gettler’s Talking Business podcast, released every Friday at www.acast.com/talkingbusiness

https://play.acast.com/s/talkingbusiness/talking-business2-interview-with-dr-ron-weinberger-from-emvi 

 

ends

Dimerix shows promise in treating ‘orphan’ kidney disease

By Leon Gettler, Talking Business

ONE OF the most debilitating diseases is FSGS (focal segmental glomerulosclerosis). It’s a rare disease where scar tissue develops on the glomeruli, the small parts of the kidneys that filter waste from the blood.

Because of its rarity – and hence its relatively low levels of research toward a treatment – the pharmaceutical world calls it an ‘orphan’ disease.

The disease can affect everyone, including children as young as two. Kidney transplants have a 60 percent failure rate. The answer lies with getting the right medication, which at the moment does not exist.

But a Melbourne based biopharmaceutical company, Dimerix, listed on the ASX, is now developing the drug to treat it.

“Our lead asset is a compound called DMX200 and that’s in phase 3 clinical trials,” Dimerix managing director Nina Webster told Talking Business.

She said sadly the prognosis was poor for patients with FSGS – and the causes of the disease at this stage are unknown. 

“There is no drug approved anywhere in the world and unfortunately kidney failure is within five years of diagnosis,” Ms Webster said.

She said nobody yet knows why kidney transplants do not help patients with FSGS.

 

Dimerix began working on drug in 2012

Ms Webster said Dimerix was founded in 2004 but the team had been working on DMX200 since 2012. Although the company had been working on it for more than a decade, she said, from a biopharmaceutical perspective that was ‘a relatively short period of time’.

She said the phase 3 clinical trial was the final one and was open globally in 11 countries and there were seven clinical sites recruiting FSGS patients for the 2024 program.

“We would expect to see the second interim outcome from this study and, if successful, we can submit for marketing approval at that point in time because it is a rare disease,” Ms Webster said.

“It is expected to be on the market in 2025.”

Ms Webster said developing drugs in the biopharmaceutical sector usually took around 10 to 15 years. She said this attracted a particular kind of investor.

“You have a particular kind of investor who has an appetite for investment in biotech,” she said. “In biotech, when we get success, success is very big and therefore while the risk is potentially higher, the reward is also a magnitude higher.”

 

Melbourne-based breakthrough

The company has 12 employees working in Melbourne, each focusing on areas such as clinical work, regulatory areas, manufacturing and intellectual property.

“Each of our team members is very experienced in drug development and has taken products from inception to marketing approval in the past.

“With no treatment anywhere in the world for FSGS, it is a big unmet need,” Ms Webster said.

“So if DMX 200 is successful in this trial, there is certainly a very big market.”

Such a big market, that it could generate huge revenues to justify the investment the company has put into developing the drug.

“The reason it’s so attractive to us in the first instance is because it’s an orphan disease, it means we have a faster pathway to market, we get an accelerated review period,” Ms Webster said.

“We also get what’s called orphan drug pricing. Now because there are fewer patients who have the disease, there has to be an incentive for companies to develop the drug.

“Orphan drug pricing is a lot higher. The orphan drug in the US retails at $7000 per month.”

www.dimerix.com

www.leongettler.com

 

Hear the complete interview and catch up with other topical business news on Leon Gettler’s Talking Business podcast, released every Friday at www.acast.com/talkingbusiness.

https://shows.acast.com/talkingbusiness/episodes/talking-business-3-intervie-with-nina-webster-from-dimerix

 

ends

Neuren Pharmaceuticals triggers up Australian biotech investment

By Leon Gettler, Talking Business >>

THE TREMENDOUS SUCCESS of Neuren Pharmaceuticals (ASX:NEU), the only biotech worldwide that specialises in neurodevelopmental disorders – and best-known for developing Daybue, a world-first treatment for Rett syndrome – is sending a signal to venture capital in Australia to start investing in biotech.

Daybue was launched in the United States in April by Neuren’s licensee, NASDAQ-listed Acadia Pharmaceuticals. The partnership with Acadia was recently expanded from North America to global, with Neuren receiving an upfront payment of US$100m. Neuren receives milestone payments and quarterly royalties on all commercial sales. 

Neuren is now focused on developing a second drug, NNZ-2591, for an additional four rare neurological disorders. Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

Neuren granted ‘orphan drug’ status in US

Topline results for Phelan-McDermid are expected December this year.  Recognising the urgent unmet need, all programs have been granted ‘orphan drug’ designation in the US. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

Generally, venture capital has been reluctant to invest in biotech companies in Australia as it has been seen as too risky.

Neuren Pharmaceuticals CEO Joh Pilcher said that could change with success stories like Neuren. 

“People are going to invest if they see examples of success and we’ve had a few of those now,” Mr Pilcher told Talking Business.

“That shows people what the end value can be and that incentivises them to invest.

“Technology is moving forward the whole time. You might argue there’s less risk than there used to be because we know so much more about biology.”

World first treatment for Rett syndrome

Mr Pilcher said the major challenge for his company was being the first in the world to develop a drug to treat Rett syndrome, a serious neurological disorder that emerges in early childhood.

It affects every aspect of life including walking, talking, breathing, sleeping, hand use and cognitive function. It mainly affects girls and there’s never been any treatment for it.

The drug itself doesn’t fix the mutation. It is not designed to treat one particular symptom. Instead, it focuses on trying to improve the connectivity between the brain cells.

“That’s what’s wrong in Rett syndrome,” Mr Pilcher said. “The connection between the brain cells – and  the signalling that’s happening between them – is not happening properly.

“That’s what our drug is trying to improve and you see impacts across a number of different things. 

“We’re getting stories coming out of the community. Things like improved communication, improved ability to use the hands for purposeful things, even improvements in walking.

“It’s a very exciting time after a long journey.”

Neuren has been developing the drug to treat Rett syndrome for the last 10 years and it has been a huge but vital challenge for the $1.5 billon biotech company.

Mr Pilcher been with the company right from the start and he said he and his team had learned so much. 

“We’ve had to show motivation and determination to get through,” he said. “In some of those periods, we weren’t in the great position we’re in now – not much cash, not great market support – we had to make sure we got through despite that.

“And the other thing is nobody had done anything in Rett syndrome before. We weren’t following what anyone else did. We had to create the path for ourselves.”

www.neurenpharma.com

www.leongettler.com

 

Hear the complete interview and catch up with other topical business news on Leon Gettler’s Talking Business podcast, released every Friday at www.acast.com/talkingbusiness.

https://play.acast.com/s/talkingbusiness/talking-business-35-interview-with-jon-pilcher-from-neuren-p

ends

UniSC researchers confront how to build ‘the best’ human-AI teams

ARTIFICIAL intelligence (AI) and humans do not have an ‘ideal working relationship’ yet – that much is clear to three researchers at the University of the Sunshine Coast (UniSC) who are investigating this complex and urgent issue.

A team led by UniSC’s Centre for Human Factors and Sociotechnical Systems has been awarded $603,000 in Australian Research Council Discovery Project funding over three years, to develop a new model of teamwork for what are known as Human-Autonomy Teams (HATs).

Centre co-director, professor Paul Salmon is leading the project to investigate how to best design artificial intelligence, and organise teams so that humans and artificial intelligence can work together effectively across multiple industries.

“Often artificial intelligence is not designed in a way that allows humans to work with it very well, so it can be a problematic team member that increases the likelihood of teamwork failures,” Prof. Salmon said. 

“An autonomous vehicle collision is a good example of where you have very advanced AI, but often it’s not telling its human teammate what it can see and what action needs to be taken, which shows us that team situational awareness and communication are still lacking.”

Yet AI is being adopted globally in workplaces at a rapid rate – across healthcare, aviation, defence, transport, and disaster response – from driverless vehicles to robot-assisted surgery.

“There are huge potential benefits,” Prof. Salmon said. “But AI is complex and is often not designed to work in teams or with consideration for how humans are going to interact with it.

“A lot of research exists on the psychology of human teams, but now we need a basic understanding of what teamwork looks like when you have humans and AI working together.

“We plan to apply new systems analysis and computational modelling methods to develop, test and validate a new model of teamwork for humans and AI. This will clarify the processes and behaviours that support optimal functioning and performance.” 

Prof. Salmon is joined on the research team by UniSC associate professor Gemma Read and Dr Scott McLean, as well as global leaders in team leadership from universities in the United States.

UniSC vice-chancellor and president, Prof. Helen Bartlett said UniSC’s Centre for Human Factors and Sociotechnical Systems was an Australian leader in how humans work effectively with systems.

“This funding is testament to the expertise of our team from UniSC, which has partnered with world experts in team-building and human autonomy from Arizona State University and Rice University,” Prof. Bartlett said.

“This project builds on our commitment to the United Nations Sustainable Development Goals, which includes contributing to (the goals of) Decent Work and Economic Growth as well as Industry, Innovation, and Infrastructure.

“We are delighted, that as a regional Australian university, we are at the forefront of new globally important research to build knowledge in these areas.”

www.usc.edu.au

 

ends

Coviu has Australia’s telehealth covered

By Leon Gettler, Talking Business >>

TELEHEALTH, the process of getting health care remotely, has taken off in Australia.

According to Coviu co-founder Silvia Pfeiffer, the practice is now well accepted among all age groups. Coviu – a spinout of CSIRO’s Data61 division – is today Australia’s leading video telehealth solution provider.

“The pandemic has given telehealth a kick in the behind,” Dr Pfeiffer, the CEO and co-founder of Coviu, told Talking Business.

“All the objections to telehealth before the pandemic fell away during the pandemic and both clinicians and patients embraced it.”

Dr Pfeiffer said telehealth was now not only used by general practitioners (GPs) but also in counselling and mental health services. 

Easy to use and accessible

Coviu’s video platform, similar to Zoom, allows clinicians to offer video consultations for their patients. That includes GPs, mental health practitioners, physical therapy practitioners, dieticians, nutritionists and medical specialists who provide a video service.

“Patients have got a real taste for it through the pandemic,” Dr Pfeiffer said.

“Think of a family, of a mother with three children and one child is sick and having to go to all kinds of efforts to get somebody to look after the children while she takes one of them to the doctor. How much easier is it to just do a video call with your GP?

“We have seen that over and over again. Patients have loved the simplicity with which they can go see a clinician online,” she said.

More importantly, Coviu has conducted research that revealed nearly half the number of Australians would switch doctors to one that offered video consultations.

The research into more than 1000 Australians found that 70 percent felt that all GPs should offer telehealth. This was across every age group.

The research also found 44 percent said they would switch GPs if they had a choice between a GP who offered telehealth and one who did not.

Patient age is no barrier

While younger Australians are less committed to their GPs, the result is similar across age groups.

Dr Pfeiffer said older Australians had really tuned into telehealth. 

“Even some as old as 99 to 100, they have embraced video telehealth because they find it so much easier than having to organise getting to a GP and asking a family member to take them,” she said.

Dr Pfeiffer said telehealth also offered opportunities in aged care and residential care.

“Right now, if you have people in aged care centres and they need to see their clinician, at the moment the GPs would have to travel out to them,” she said. “Often the GPs don’t have a lot of time, [so] they go through in a rush and they might not come often enough.

“If video telehealth can be introduced in an aged care [facility], they can just make an appointment when it’s needed without waiting for the next doctor’s regular visit to come to the centre.”

Dr Pfeiffer said it was “not really an issue” of whether older Australians would accept that, as many older Australians had already embraced telehealth, just as they had embraced video technology to stay in touch with their families.

“It’s more a personal preference problem,” she said. “Some people are very good with picking up technology and feeling comfortable talking on video and other people cannot deal with it. They absolutely have to go and see their clinicians face to face.”

www.coviu.com

www.leongettler.com 

 

Hear the complete interview and catch up with other topical business news on Leon Gettler’s Talking Business podcast, released every Friday at www.acast.com/talkingbusiness.

https://play.acast.com/s/talkingbusiness/talking-business19-interview-with-dr-silvia-pfeiffer-from-co

ends

Contact Us

 

PO Box 2144
MANSFIELD QLD 4122